期刊文献+

STAT3在小细胞肺癌中的表达及对血管生成的影响 被引量:3

STAT3 Expression in Small Cell Lung Cancer and Angiogenesis
下载PDF
导出
摘要 目的探讨信号传导和转录激活因子(STAT3)及其磷酸化形式p-STAT3在小细胞肺癌(SCLCs)中的表达及STAT3与小细胞肺癌血管生成的关系。方法收集64例小细胞肺癌患者的肺癌组织及癌旁正常肺组织,采用WesternBlot检测组织中STAT3和p-STAT3的蛋白表达,采用RT-PCR法检测组织中STAT3的mRNA表达,同时观察组织中微血管密度(MVD)的水平。结果与正常肺组织相比,小细胞肺癌组织中STAT3和p-STAT3的蛋白表达以及STAT3的mRNA表达水平均明显升高(P<0.05)。肺癌组织STAT3和p-STAT3的表达水平与患者的总生存率、淋巴结转移,临床分期和肿瘤大小正相关(P<0.05)。STAT3的表达与肺癌组织中MVD的水平成正相关。结论 STAT3及其磷酸化形式在小细胞肺癌的表达升高,且其与小细胞肺癌患者的临床病理特征具有相关性,可能是临床治疗的新靶点。 Objective To investigate expressions of signal transduction and activator of transcription factor (STAT3) and its phosphorylated form (p-STAT3) in small cell lung cancer (SCLCs), and the relations with vascular generated. Methods Lung cancer group was lung tissue of 64 patients with small cell lung cancer and its surrounding normal lung tissue as control group. Western Blot was used to detect STAT3 and p-STAT3 protein expression and RT-PCR. was used to analysis STAT3 mRNA expression, while observing the level of both tissue microvascular densities (MVD). Results Compared with normal lung tis-sue, STAT3 and p-STAT3 mRNA and protein levels in Lung cancer group were significantly increased (P〈 0.05). STAT3 and p-STAT3 expressions in the lung tissue were positively related to survival, lymph node metastasis, clinical stage, and minor size (P〈 0.05). STAT3 expression in lung tissue was positively reLated to MVD levels. Conclusion STAT3 plays an important role in the occurrence and development of small cell lung cancer, and STAT3 maybe a new target for small cell lung cancer.
出处 《肿瘤药学》 CAS 2013年第3期176-179,共4页 Anti-Tumor Pharmacy
基金 湖南省科技厅科技计划项目资助(2012SK3249)
关键词 信号传导和转录激活因子 磷酸化信号传导和转录激活因子 小细胞肺癌 微血管密度 Signal transduction and transcription activator Phosphoryhtion signal transducfon and activator of transcription Small cell lung cancer Microvessel density
  • 相关文献

参考文献16

  • 1朱湘平,姜正华,黄谦,姚汉清,王正东,徐兴祥.培美曲塞联合卡铂治疗老年晚期非鳞非小细胞肺癌临床疗效分析[J].临床肺科杂志,2013,18(2):229-230. 被引量:15
  • 2Gest C,Mirshahi P,Li H. Ovarian cancer:Stat3,RhoA and IGF-IR as therapeutic targets[J].{H}CANCER LETTERS,2012,(02):207-217.
  • 3Ting CM,Wong CKC,Wong RNS. Role of STAT3/5 and Bcl-2/xL in 2-methoxyestradiol-induced endoreduplication of nasopharyngeal carcinoma cells[J].{H}Molecular Carcinogenesis,2012,(12):963-972.
  • 4Huang C,Huang R,Chang W. The expression and clinical significance of pSTAT3,VEGF and VEGF-C in pancreatic adenocarcinoma[J].{H}NEOPLASMA,2012,(01):52.
  • 5Maemondo M,Minegishi Y,Inoue A. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations:NEJ 003 Study[J].J Thoracic Oncol,2012,(09):1417-1422.
  • 6Govindan R,Page N,Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epide-miologic,and end results database[J].{H}Journal of Clinical Oncology,2006,(28):4539-4544.
  • 7Wang W,Taylor RN,Bagchi IC. Regulation of Human Endometrial Stromal Proliferation and Differentia-tion by C/EBPβ Involves Cyclin E-cdk2 and STAT3[J].{H}Molecular Endocrinology,2012,(12):2016-2030.
  • 8Tseng LM,Huang PI,Chen YR. Targeting Signal Transducer and Activator of Transcription 3 Pathway by Cucurbitacin I Diminishes Self-Renewing and Radioche-moresistant Abilities in Thyroid Cancer-Derived CD133+ Cells[J].{H}Journal of Pharmacology and Experimental Therapeutics,2012,(02):410-423.
  • 9Kharaziha P,De Raeve H,Fristedt C. Sorafenib has potent antitumor activity against multiple myeloma in vi-tro,ex vivo,and in vivo in the 5T33MM mouse model[J].{H}CANCER RESEARCH,2012,(20):5348-5362.
  • 10佘晓玲,刘保安.Stat3与肿瘤的侵袭转移[J].现代生物医学进展,2007,7(2):298-300. 被引量:3

二级参考文献19

  • 1王瑾,许峰,周清华.肺癌流行病学研究进展[J].中国肺癌杂志,2005,8(5):395-400. 被引量:59
  • 2唐古生,蔡建明,倪瑾,项莺松,崔建国,朱丹,董俊瑞.反义STAT3对肿瘤细胞增殖抑制和诱导凋亡的作用[J].癌症,2006,25(3):269-274. 被引量:18
  • 3Brown T, Boland A, Bagust A,et al. Gefitinib for the first-linetreatment of locally advanced or metastatic non-small cell lung canc-er[ J]. Health Technol Assess, 2010,14(2) :71 -79.
  • 4Nuijten MJ, Aultman R, Carpeno J, et al. An indirect comparisonof the efficacy of bevacizumab plus carboplatin and paclitaxel versuspemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non - small cell lung cancer[ J]. Cur-rent medical research and opinion, 2011 ,27(11) :2193 -2201.
  • 5Zhao Mei,Gao Feng-hou. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer original research article[J].Lung Cancer September,2011,(03):366-374.
  • 6汤钊猷.现代肿瘤学[M]上海:复旦大学出版社,20111020-1021.
  • 7Sen B,Saigal B,Parikh N. Sustained src inhibition results in signal transducer and activator of transcription 3(STAT3)acti vation and cancer cell survival via altered Janus activated kinase STAT3 binding[J].Cancer Research,2009,(05):1958-1965.
  • 8Darnell JE Jr. Transcription factors as targets for cancer therapy[J].Nature Reviews Cancer,2002,(10):740-749.
  • 9Buettner R,Mora LB,Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention[J].Clinical Cancer Research,2002,(04):945-954.
  • 10Shirogane T,Fukada T,Muller JM. Synergistic roles for pim-1 and c-Myc in STAT3 mediated cell cycle progression and antiapoptosis[J].Immunity,1999,(06):709-719.

共引文献17

同被引文献38

引证文献3

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部